Treating Women's Sexual Desire and Arousal Problems

Both, Stephanie; Schultz, Willibrord Weijmar; Laan, Ellen

doi:10.1002/9781118510384.ch2

Cited by 4 publications

(2 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Facilitation of sexual responsiveness will not change the negative meaning of sex as stored in memory. CBT to diminish fear or disgust and sex therapy interventions to acquire positive associations with sex will likely be more helpful [ 40 ]. Furthermore, when there are conflicts in the relational context, poor communication, or a lack of intimacy, a woman may be reluctant to respond to sexual stimulation.…”

Section: Recent Developments In Psychopharmacological Treatment Of Fsmentioning

confidence: 99%

Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder

Both

2017

Curr Sex Health Rep

Self Cite

View full text Add to dashboard Cite

Purpose of ReviewThis review summarizes the recent literature and empirical studies on psychopharmacological approaches to treating female sexual interest/arousal disorder (FSIAD).Recent FindingsSeveral new drugs for FSIAD that are intended to increase sexual responsiveness by influencing central excitatory and inhibitory neuromodulatory processes are under development. Studies on flibanserin resulted in the first approved medication for the treatment of low sexual desire in premenopausal women. New drugs under development are testosterone combined with sildenafil or buspiron, bremelanotide, BP101, and nasal testosterone (TBS-2).SummaryAlthough pharmacological enhancement of sexual responsiveness may be potentially helpful in the treatment of FSIAD, the observed effects of flibanserin and other new drugs under development seem limited in terms of clinical significance. Given the multifactorial character of FSIAD, it may be important to integrate psychopharmacological treatment with sex therapy for optimal treatment efficacy.

show abstract

Section: Recent Developments In Psychopharmacological Treatment Of Fsmentioning

confidence: 99%

Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder

Both

2017

Curr Sex Health Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, pharmacological enhancement of CBT for disorders characterized by maladaptive low motivation may also be an interesting option. CBT for maladaptive low motivation such as in anhedonia or low sexual interest strives to target deficits in appetitive responding, by enhancing the anticipation, consumption and learning of reward (Both, Laan, & Schultz 2010;Both et al 2017b;Craske et al 2016;ter Kuile et al 2010). A recent study in rats showing a facilitating effect of a new NMDA agonist, Rapastinel, on positive emotional learning (Khan et al 2018), and older studies showing enhancing effects of DCS on socio-sexual behaviour (McAllister 1994) and conditioned flavour-taste preference (Golden and Houpt 2007), indicate that DCS may be helpful in the facilitation of appetitive learning.…”

mentioning

confidence: 99%

A randomized, placebo-controlled laboratory study of the effects of D-cycloserine on sexual memory consolidation in women

et al. 2020

View full text Add to dashboard Cite

Rationale and objective The aim of this study was to investigate the possible facilitating effect of the partial NMDA receptor agonist D-cycloserine (DCS) on memory consolidation of conditioned sexual responses and to examine the capability of DCS to reduce context-specificity of learning. Methods In a randomized placebo-controlled double-blind trial, 50 healthy females were exposed to a differential conditioning procedure. Two pictures of a male abdomen were used as conditional stimuli (CSs), of which one (the CS+) was followed by the unconditional stimulus (US), a genital vibrotactile stimulus. After the conditioning session on day 1, participants received either 125 mg of DCS or a placebo. The effects of DCS on affect, sexual arousal and US expectancy in response to the CS+ and CS− were examined 24 h after the conditioning procedure.Results A main effect of DCS was found on affect at the first test trials (p = 0.04, η p 2 = 0.09), and a similar non-significant but trend level effect was found for sexual arousal (p = 0.06, η p 2 = 0.07), which appeared to persist over a longer time (p = 0.07, η p 2 = 0.08). Unexpectedly, ratings of positive affect and sexual arousal in response to both the CS+ and the CS− were higher in the DCS condition compared to the control condition, possibly indicating that DCS administration reduced stimulus specificity. Since the results did not show clear evidence for context learning, we were not able to test effects on context-specificity of learning. Conclusion Although largely inconclusive, the results provide tentative support for a facilitating effect of DCS on affect and sexual arousal in response to stimuli that were presented in a sexual conditioning procedure, however, no conclusions can be drawn about effects of DCS on sexual reward learning, since the design and results do not lend themselves to unambiguous interpretation.

show abstract

Why is absent/low sexual desire a mental disorder (except when patients identify as asexual)?

Margolin

2023

Psychology & Sexuality

View full text Add to dashboard Cite

Treating Women's Sexual Desire and Arousal Problems

Cited by 4 publications

References 149 publications

Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder

Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder

A randomized, placebo-controlled laboratory study of the effects of D-cycloserine on sexual memory consolidation in women

Why is absent/low sexual desire a mental disorder (except when patients identify as asexual)?

Contact Info

Product

Resources

About